Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes
Abstract
BACKGROUND & AIMS: Faecalibacterium prausnitzii, a highly abundant gut bacterium, has been linked to overall health, and is decreased in several pathologic conditions, such as inflammatory bowel disease (IBD). F prausnitzii has shown anti-inflammatory properties in human and mouse models, notably through the induction of interleukin 10 (IL10) signaling. Here, we investigated which cell types from human blood and intestinal tissue are responsible for producing IL10 induced by F prausnitzii and provide the first mechanistic insights. METHODS: Immune cells isolated from human blood and intestinal lamina propria of IBD patients and noninflamed controls, were stimulated with F prausnitzii EXL01 strain, Coprococcus comes 27758 strain, and Escherichia coli MG1655 strain, with or without lipopolysaccharide (LPS), and analyzed by LEGENDplex, enzyme-linked immunosorbent assay, flow cytometry, RNA sequencing, and Seahorse technology. RESULTS: monocytes from the systemic circulation and intestinal tissue, without inducing a proinflammatory response compared with LPS stimulation. RNA sequencing and Seahorse analyses corroborated these results, revealing that F prausnitzii affects cellular energy metabolism in healthy and inflammatory conditions, in a different way from 2 other tested bacteria and LPS. The anti-inflammatory response induced by F prausnitzii in monocytes was dependent on mitochondrial respiration. CONCLUSIONS: F prausnitzii induces an anti-inflammatory response and rewires energy metabolism in human monocytes in healthy and inflamed conditions, potentially explaining its beneficial impact on intestinal inflammation and human health in general. These results provide new insight into the mechanisms underlying the anti-inflammatory effects of F prausnitzii and are crucial for a better understanding of its potential use in IBD treatment.
Related
- Baseline co-occurrence of Faecalibacterium prausnitzii and Ruminococcus bromii is associated with greater increases in selected short-chain fatty acid-related pathways following resistant starch type 2 intervention across diverse populations
- Faecalibacterium prausnitzii in neurological disorders: mechanistic links and therapeutic potential along the microbiota–gut–brain axis
- Faecalibacterium prausnitzii in the gut protects against acute lung injury in influenza through butyrate educated reparative CD4⁺T cells.
- Metabolic reprogramming and metabolic homeostasis in podocyte injury: novel mechanistic insights and natural product therapies
- Nrf2 and AhR in metabolic reprogramming after contaminant exposure
BibTeX
@article{danne2026faecalibacterium,
title = {{Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes}},
author = {Camille Danne and Rodrigo de Oliveira Formiga and Laura Creusot and Florian Marquet and Delphine Sedda and Laura Hua and Pauline Ruffié and Hang-Phuong Pham and Loic Brot and Iria Alonso Salgueiro and Marie-Laure Michel and Philippe Langella and Jérémie Lefevre and Harry Sokol and Nathalie Rolhion},
journal = {Gastroenterology},
year = {2026},
month = nov,
doi = {10.1053/j.gastro.2025.10.003},
url = {https://hal.science/hal-05848912v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes
AU - Camille Danne
AU - Rodrigo de Oliveira Formiga
AU - Laura Creusot
AU - Florian Marquet
AU - Delphine Sedda
AU - Laura Hua
AU - Pauline Ruffié
AU - Hang-Phuong Pham
AU - Loic Brot
AU - Iria Alonso Salgueiro
AU - Marie-Laure Michel
AU - Philippe Langella
AU - Jérémie Lefevre
AU - Harry Sokol
AU - Nathalie Rolhion
PY - 2026
DA - 2026/11/02
JO - Gastroenterology
DO - 10.1053/j.gastro.2025.10.003
UR - https://hal.science/hal-05848912v1
AB - BACKGROUND & AIMS: Faecalibacterium prausnitzii, a highly abundant gut bacterium, has been linked to overall health, and is decreased in several pathologic conditions, such as inflammatory bowel disease (IBD). F prausnitzii has shown anti-inflammatory properties in human and mouse models, notably through the induction of interleukin 10 (IL10) signaling. Here, we investigated which cell types from human blood and intestinal tissue are responsible for producing IL10 induced by F prausnitzii and provide the first mechanistic insights. METHODS: Immune cells isolated from human blood and intestinal lamina propria of IBD patients and noninflamed controls, were stimulated with F prausnitzii EXL01 strain, Coprococcus comes 27758 strain, and Escherichia coli MG1655 strain, with or without lipopolysaccharide (LPS), and analyzed by LEGENDplex, enzyme-linked immunosorbent assay, flow cytometry, RNA sequencing, and Seahorse technology. RESULTS: monocytes from the systemic circulation and intestinal tissue, without inducing a proinflammatory response compared with LPS stimulation. RNA sequencing and Seahorse analyses corroborated these results, revealing that F prausnitzii affects cellular energy metabolism in healthy and inflammatory conditions, in a different way from 2 other tested bacteria and LPS. The anti-inflammatory response induced by F prausnitzii in monocytes was dependent on mitochondrial respiration. CONCLUSIONS: F prausnitzii induces an anti-inflammatory response and rewires energy metabolism in human monocytes in healthy and inflamed conditions, potentially explaining its beneficial impact on intestinal inflammation and human health in general. These results provide new insight into the mechanisms underlying the anti-inflammatory effects of F prausnitzii and are crucial for a better understanding of its potential use in IBD treatment.
SN - 0016-5085
SN - 1528-0012
ER -